375 related articles for article (PubMed ID: 29311125)
1. Molecular Biomarkers in the Clinical Management of Prostate Cancer.
Udager AM; Tomlins SA
Cold Spring Harb Perspect Med; 2018 Nov; 8(11):. PubMed ID: 29311125
[TBL] [Abstract][Full Text] [Related]
2. Overdiagnosis and overtreatment of prostate cancer.
Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
[TBL] [Abstract][Full Text] [Related]
3. Recent progress and perspectives on prostate cancer biomarkers.
Hatakeyama S; Yoneyama T; Tobisawa Y; Ohyama C
Int J Clin Oncol; 2017 Apr; 22(2):214-221. PubMed ID: 27730440
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNAs in prostate cancer: Functional roles and clinical implications.
Xu YH; Deng JL; Wang G; Zhu YS
Cancer Lett; 2019 Nov; 464():37-55. PubMed ID: 31465841
[TBL] [Abstract][Full Text] [Related]
5. Approaches to urinary detection of prostate cancer.
Eskra JN; Rabizadeh D; Pavlovich CP; Catalona WJ; Luo J
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):362-381. PubMed ID: 30655600
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer overdiagnosis and overtreatment.
Klotz L
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):204-9. PubMed ID: 23609043
[TBL] [Abstract][Full Text] [Related]
7. Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
Narayan VM; Konety BR; Warlick C
Int J Urol; 2017 May; 24(5):352-360. PubMed ID: 28345187
[TBL] [Abstract][Full Text] [Related]
8. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
Lieberman R
Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
[TBL] [Abstract][Full Text] [Related]
9. Are localized prostate cancer biomarkers useful in the clinical practice?
Carneiro A; Priante Kayano P; Gomes Barbosa ÁR; Langer Wroclawski M; Ko Chen C; Cavlini GC; Reche GJ; Sanchez-Salas R; Tobias-Machado M; Sowalsky AG; Bianco B
Tumour Biol; 2018 Sep; 40(9):1010428318799255. PubMed ID: 30204063
[TBL] [Abstract][Full Text] [Related]
10. Beyond PSA: the next generation of prostate cancer biomarkers.
Prensner JR; Rubin MA; Wei JT; Chinnaiyan AM
Sci Transl Med; 2012 Mar; 4(127):127rv3. PubMed ID: 22461644
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review.
Liss MA; Leach RJ; Sanda MG; Semmes OJ
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2454-2462. PubMed ID: 33093161
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review.
Endzeliņš E; Melne V; Kalniņa Z; Lietuvietis V; Riekstiņa U; Llorente A; Linē A
Mol Cancer; 2016 May; 15(1):41. PubMed ID: 27189160
[TBL] [Abstract][Full Text] [Related]
13. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
VanderWeele DJ; Finney R; Katayama K; Gillard M; Paner G; Imoto S; Yamaguchi R; Wheeler D; Lack J; Cam M; Pontier A; Nguyen YTM; Maejima K; Sasaki-Oku A; Nakano K; Tanaka H; Vander Griend D; Kubo M; Ratain MJ; Miyano S; Nakagawa H
Eur Urol Focus; 2019 May; 5(3):416-424. PubMed ID: 29398457
[TBL] [Abstract][Full Text] [Related]
14. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
15. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
16. Cancer overdiagnosis and overtreatment.
Klotz L
Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
[TBL] [Abstract][Full Text] [Related]
17. Prevention and early detection of prostate cancer.
Cuzick J; Thorat MA; Andriole G; Brawley OW; Brown PH; Culig Z; Eeles RA; Ford LG; Hamdy FC; Holmberg L; Ilic D; Key TJ; La Vecchia C; Lilja H; Marberger M; Meyskens FL; Minasian LM; Parker C; Parnes HL; Perner S; Rittenhouse H; Schalken J; Schmid HP; Schmitz-Dräger BJ; Schröder FH; Stenzl A; Tombal B; Wilt TJ; Wolk A
Lancet Oncol; 2014 Oct; 15(11):e484-92. PubMed ID: 25281467
[TBL] [Abstract][Full Text] [Related]
18. The role of genetic markers in the management of prostate cancer.
Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
[TBL] [Abstract][Full Text] [Related]
19. The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy.
Faisal FA; Lotan TL
Adv Anat Pathol; 2020 Jan; 27(1):11-19. PubMed ID: 31503032
[TBL] [Abstract][Full Text] [Related]
20. Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis.
Troyer DA; Mubiru J; Leach RJ; Naylor SL
Dis Markers; 2004; 20(2):117-28. PubMed ID: 15322319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
